When to initiate HIV therapy: a control theoretic approach
暂无分享,去创建一个
[1] Denise E. Kirschner,et al. Using Mathematics to Understand HIV Immune Dynamics , 1997 .
[2] R Brookmeyer,et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. , 1997, Science.
[3] Louis J. Picker,et al. Changes in thymic function with age and during the treatment of HIV infection , 1998, Nature.
[4] T Hraba,et al. Model-based analysis of CD4+ lymphocyte dynamics in HIV infected individuals. , 1990, Immunobiology.
[5] M. Nowak,et al. Virus dynamics: Mathematical principles of immunology and virology , 2001 .
[6] N M Ferguson,et al. Viral dynamics and anti-viral pharmacodynamics: rethinking in vitro measures of drug potency. , 2001, Trends in pharmacological sciences.
[7] M A Nowak,et al. Pre-existence and emergence of drug resistance in HIV-1 infection. , 1997, Proceedings. Biological sciences.
[8] Xiaohua Xia,et al. Estimation of HIV/AIDS parameters , 2003, Autom..
[9] Xiaohua Xia,et al. CONTROLLABILITY ANALYSIS OF THE CHEMOTHERAPY OF HIV/AIDS , 2002 .
[10] S. Hammer,et al. Zidovudine: Five Years Later , 1992, Annals of Internal Medicine.
[11] A. Swart. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection , 1994, The Lancet.
[12] Alan S. Perelson,et al. Dynamics of HIV Infection , 2003 .
[13] Denise Kirschner,et al. A model for treatment strategy in the chemotherapy of AIDS , 1996 .
[14] A. Perelson,et al. HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time , 1996, Science.
[15] J W Mulder,et al. The effect of plasma drug concentrations on HIV‐1 clearance rate during quadruple drug therapy , 1998, AIDS.
[16] T. Chun,et al. Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[17] M. Nowak,et al. Pre–existence and emergence of drug resistance in HIV–1 infection , 1997, Proceedings of the Royal Society of London. Series B: Biological Sciences.
[18] X. Xia. ESTIMATION OF HIV/AIDS PARAMETERS , 2002 .
[19] Glenn F. Webb,et al. Model of HIV-1 disease progression based on virus-induced lymph node homing and homing-induced apoptosis of CD4+ lymphocytes. , 2000 .
[20] José Álvarez-Ramírez,et al. Feedback Control of the chemotherapy of HIV , 2000, Int. J. Bifurc. Chaos.
[21] J.A.M. Felippe de Souza,et al. Optimal control theory applied to the anti-viral treatment of AIDS , 2000, Proceedings of the 39th IEEE Conference on Decision and Control (Cat. No.00CH37187).
[22] Sebastian Bonhoeffer,et al. Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis , 1999, The Lancet.
[23] D. Kirschner,et al. Optimal control of the chemotherapy of HIV , 1997, Journal of mathematical biology.
[24] Alan S. Perelson,et al. Mathematical Analysis of HIV-1 Dynamics in Vivo , 1999, SIAM Rev..
[25] M. Nowak,et al. Dynamic multidrug therapies for HIV: a control theoretic approach. , 2015, Journal of theoretical biology.
[26] Ian Postlethwaite,et al. Multivariable Feedback Control: Analysis and Design , 1996 .
[27] D. Richman,et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. , 1997, Science.
[28] Guanrong Chen,et al. Feedback control of a biodynamical model of HIV-1 , 2001, IEEE Transactions on Biomedical Engineering.
[29] W. Tan,et al. Stochastic modeling of the dynamics of CD4+ T-cell infection by HIV and some Monte Carlo studies. , 1998, Mathematical biosciences.